Dose-dependent decrease in hepatitis delta virus (HDV) RNA achieved with the oral prenylation inhibitor lonafarnib in a proof-of-concept, randomised, double-blinded, placebo-controlled study in patients with chronic HDV infection
Titel:
Dose-dependent decrease in hepatitis delta virus (HDV) RNA achieved with the oral prenylation inhibitor lonafarnib in a proof-of-concept, randomised, double-blinded, placebo-controlled study in patients with chronic HDV infection
Auteur:
Koh, C. Canini, L. Dahari, H. Cooper, S. Cory, D. Winters, M.A. Choong, I. Cotler, S.J. Kleiner, D.E. Yurdaydin, C. Heller, T. Glenn, J.S.